Mitsubishi UFJ Asset Management UK Ltd. Boosts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

by · The Cerbat Gem

Mitsubishi UFJ Asset Management UK Ltd. increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 250.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,800 shares of the medical equipment provider’s stock after purchasing an additional 7,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Lantheus were worth $1,076,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus in the 3rd quarter valued at about $51,000. Fidelis Capital Partners LLC purchased a new position in Lantheus during the first quarter worth about $34,000. Finally, Nkcfo LLC acquired a new stake in shares of Lantheus during the second quarter valued at about $47,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 0.9 %

Shares of LNTH stock traded up $1.04 during trading hours on Friday, reaching $116.69. 516,835 shares of the stock were exchanged, compared to its average volume of 972,978. The business’s fifty day moving average is $105.80 and its two-hundred day moving average is $90.92. The firm has a market capitalization of $8.09 billion, a P/E ratio of 17.82 and a beta of 0.50. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.40 earnings per share. As a group, research analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Activity

In related news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,981 shares of company stock worth $2,689,156. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LNTH shares. Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Finally, Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $126.00.

Read Our Latest Analysis on LNTH

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).